Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations.

by Manuela Vecsler, Bruria Ben Zeev, Igor Nudelman, Yair Anikster, Amos J Simon, Ninette Amariglio, Gideon Rechavi, Timor Baasov, Eva Gak
Published 2011-01-01